Treating hyperglycemia in type 2 diabetes: New goals and strategies

Cleveland Clinic Journal of Medicine

Volumn 69, Issue 10, 2002, Pages 809-820

  Lebovitz, Harold E ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ABDOMINAL DISCOMFORT; BLOOD GLUCOSE MONITORING; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG COST; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG USE; DYSLIPIDEMIA; EDEMA; FLATULENCE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESISTANCE; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REVIEW; WEIGHT GAIN;

EID: 0036797157     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.69.10.809     Document Type: Review

References (70)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14(suppl):7-85.
2. Aiello LP, Cavallerano JD, Gardner TW, et al. Diabetic retinopathy. Diabetes Care 1998; 21:143-156.
3. Centers for Disease Control and Prevention. 1999 Diabetes Surveillance Report. Chapter 8: End Stage Renal Disease. Available at www.cdc.gov/diabetes/statistics/survl99/chap8/contents.htm. Accessed 5/8/02.
4. Mayfield JA, Janisse D, Reiber GE, Pogach LM, Sanders LJ. Preventive foot care in people with diabetes. Diabetes Care 1998; 21:2161-2177.
5. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Diabetes in America. 2nd ed. NIH Publication No. 95-1468. 1995:429-448.
6. Bergstrom RW, Wahl PW, Leonetti DI, Fujimoto WY. Association of fasting glucose levels with a delayed secretion of insulin after oral glucose in subjects with glucose intolerance. J Clin Endocrinol Metab 1990; 71:1447-1453.
7. Lebovitz HE. Insulin secretogogues: old and new. Diabetes Reviews 1999; 7:139-153.
8. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993; 42:1663-1672.
9. UK Prospective Diabetes Study Group. Overview of 6 years therapy of type 2 diabetes: a progressive disease (UKPDS 16). Diabetes 1995; 44:1249-1258.
10. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263:2893-2898.
11. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104:787-794.
12. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001; 109(suppl 2):135-148.
13. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-689.
14. Haffner SM, Mykkänen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101:975-980.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
16. van Haeften TW, Pimenta W, Mitrakou A, et al. Relative contributions of beta-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia. Metabolism 2000; 49:1318-1325.
17. Dostou J, Gerich J. Pathogenesis of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2001; 109(suppl 2):149-156.
18. ATP channels and insulin secretion. Recent Prog Horm Res 2001; 56:47-68.
19. Clark HE, Matthews DR. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. Horm Metab Res 1996; 28:445-450.
20. Ashcroft FM. Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res 1996; 28:456-463.
21. Shapiro ET, Van Cauter E, Tillil H, et al. Glyburide enhances the responsiveness of the beta cell to glucose but does not correct the abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1989; 69:571-576.
22. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47:345-351.
23. ATP channels. J Pharmacol Exp Ther 1999; 291:1372-1379.
24. ATP channel activity and membrane-binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther 2000; 293:444-452.
25. Hatorp V, Huang WC, Strange P. Pharmacokinetic properties of repaglinide in elderly subjects with type 2 diabetes. J Clin Endocrinol Metab 1999; 84:1475-1478.
26. Walter YH, Spratt DI, Garreffa S, McLeod JF. Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus. Eur J Clin Pharmacol 2000; 56:129-133.
27. Hanefeld M, Dickinson S, Bouter KP, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000; 23:202-207.
28. Guay DRP. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus. Pharmacotherapy 1998; 18:1195-1204.
29. Damsbo P, Marbury TC, Clauson P, Windfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 1999; 22:789-794.
30. Jovanovic L, Dailey G III, Huang W-C, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: A 24-week fixed-dose efficacy and safety study. J Clin Pharmacol 2000; 40:49-57.
31. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
32. Abraira C, Henderson WG, Colwell JA, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998; 21:574-579.
33. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999; 130:389-396.
34. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am 2001: 30:935-982.
35. Yki-Jarvinen H, Dressler A, Zieman M, Study Group HOE 901/3002. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during combination therapy in type 2 diabetes. Diabetes Care 2001; 23:1130-1136.
36. Bolli G. Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2001; 109(suppl 2):317-332.
37. Bolli G, Owens DR. Insulin glargine. Lancet 2000; 356:443-445.
38. Skyler JS. Insulin treatment. In: Lebovitz H, editor. Therapy for Diabetes Mellitus and Related Disorders. 3rd ed. Alexandria, Va: American Diabetes Association, 1998:186-203.
39. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich J. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:550-554.
40. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49:2063-2069.
41. Bell PM, Hadden DR. Metformin. Endocrinol Metab Clin North Am 1997; 26:523-537.
42. Campbell IW, Howlett HCS. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev 1995; 11(suppl):57-62.
43. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type 2 diabetes mellitus. N Engl J Med 1998; 338:867-872.
44. Yu JG, Kruszynska YT, Mulford MI, Olefsky JM. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes 1999; 48:2414-2421.
45. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:541-549.
46. Bailey CJ, Turner RC. Drug therapy: metformin. N Engl J Med 1996; 334:574-579.
47. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-865.
48. Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am 2001; 30:909-933.
49. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001; 56:265-294.
50. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43:527-550.
51. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001; 70:341-367.
52. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86:280-288.
53. Miyazaki Y, Ferrannini E, Mahankali A, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24:710-719.
54. Adams M, Montague CT, Prins JB, et al. Activators of PPAR-gamma have depot-specific effects on human pre-adipocyte differentiation. J Clin Invest 1997; 100:3149-3153.
55. Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats; rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50:1021-1029.
56. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25:815-823.
57. Lebovitz HE. Alpha-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Reviews 1998; 6:132-145.
58. Raptis SA, Dimitriadis GD. Oral hypoglycemic agents: insulin secretogogues, alpha-glucosidase inhibitors and insulin sensitizers. Exp Clin Endocrinol Diabetes 2001; 109(suppl 2):265-287.
59. Chiasson JL, Josse R, Hunt J, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1994; 121:928-935.
60. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years. Diabetes Care 1999; 22:960-964.
61. DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. Diabetes 1996; 45:1289-1298.
62. Stratton IM, Adler AI, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-412.
63. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25(suppl A):S33-S49.
64. Boden G, Ruiz J, Kim CJ, Chen Y. Effects of prolonged glucose infusion on insulin secretion, clearance and action in normal subjects. Am J Physiol 1996; 270:E251-E258.
65. Marbury T, Huang W-C, Strange P, Lebovitz HE. Repaglinide vs glyburide: a 1-year comparison trial. Diabetes Res Clin Pract 1999; 43:155-166.
66. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
67. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. A randomized controlled trial. JAMA 2000; 283:1695-1702.
68. Horton ES, Foley J, Clinkingbeard C, Foley J, Mallow S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23:1660-1665.
69. Horton ES, Whitehouse F, Ghazzi MN, Venable TC, The Troglitazone Study Group, Whitcomb RW. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care 1998; 21:1462-1469.
70. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000; 22:1395-1409.